γ-Secretase modulation and its promise for Alzheimer's disease: A medicinal chemistry perspective

Current Topics in Medicinal Chemistry

Volumn 8, Issue 1, 2008, Pages 38-46

  Peretto, Ilaria ^a   La Porta, Elena ^a  

^a NiKem Research   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN[1-42]; ASPARTIC PROTEINASE; CARPROFEN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; DP 155; FARNESYL DIPHOSPHATE; FENOFIBRATE; FLURBIPROFEN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GAMMA SECRETASE MODULATOR; GERANYLGERANYL PYROPHOSPHATE; IBUPROFEN; INDOMETACIN; INDOMETACIN DERIVATIVE; METHYLFLURBIPROFEN; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; SULINDAC SULFIDE; TARENFLURBIL; ENZYME INHIBITOR; SECRETASE;

ALZHEIMER DISEASE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; IC 50; NONHUMAN; PATENT; PHARMACOPHORE; PROTEIN SYNTHESIS; REVIEW; STEADY STATE; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ENZYME INHIBITORS; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 40349106236     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802608783334097     Document Type: Review

References (33)

1. Weggen, S.; Eriksen, J. L.; Das, P.; Sagi, S. A.; Wang, R.; Pietrzik, C. U.; Findlay, K. A.; Smith, T. E.; Murphy, M. P.; Bulter, T.; Kang, D. E.; Marquez-Sterling, N.; Golde, T. E.; Koo, E. H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001, 414, 212-216.
2. Lim, G.-P.; Yang, F.; Chu, T.; Chen, P.; Beech, W.; Teter, B.; Tran, T.; Ubeda, O.; Ashe, K. H.; Frautschy, S. A.; Cole, G. M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 2000, 20, 5709-5714.
3. Eriksen, J. L.; Sagi, S. A.; Smith, T. E.; Weggen, S.; Das, P.; McLendon, D. L.; Ozols, V. V.; Jessing, K. W.; Zavitz, K. H.; Koo, E. H.; Golde, T. E. NSAIDs and emantioners of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 2003, 112, 440-449.
4. Gasparini, L.; Rusconi, I.; Xu, H.; Del Soldato, P.; Ongini, E. Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures. J. Neurochem. 2004, 88, 337-348.
5. Leuchtenberger, S.; Beher, D.; Weggen, S. Selective modulation of Abeta42 production in Alzheimer's disease: Non-steroidal anti-inflammatory drugs and beyond. Curr. Pharm. Des. 2006 12, 4337-4355.
6. Churcher I.; Williams, S.; Kerrad, S,; Harrison, T.; Castro, J. L.; Shearman, M. S.; Lewis, H. D.; Clarke, E. E.; Wrigley, J. D.; Beher, D.; Tang, Y. S.; Liu, W. Design and Synthesis of Highly Potent Benzodiazepine gamma-Secretase Inhibitors: Preparation of (2S,3R)3-(3,4- Difluorophenyl)-2-(4-fluorophenyl)-4 hydro-N-((3S)-1-methyl-2-oxo-5- phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)butyramide by Use of an Asymmetric Ireland-Claisen Rearrangement. J. Med. Chem. 2003, 46, 2275-2278.
7. Geisslinger, G.; Lotsch, J.; Menzel, S.; Kobal, G.; Brune, K. Stereoselective diposition of flurbiprofen in healthy subjects following administration of the single enantiomers. Br. J. Clin. Pharmacol. 1994, 37, 392-394.
8. http:www.myriad.com/alzheimers/flurizan.php.
9. Stock, N.; Munoz, B.; Wrigley, J. D.; Shearman, M. S.; Beher, D.; Peachey, J. Williamson, T. L.; Bain, G.; Chen, W.; Jiang, X.; St-Jacques, R.; Prasit, P. The geminal dimethyl analogue of Flurbiprofen as a novel Abeta 12 inhibitor and potential Alzheimer's disease modifying agent. Bioorg. Med. Chem. Lett. 2006, 16, 2219-2223.
10. Raveglia, L.; Peretto, I.; Radaelli, S.; Imbimbo, B. P.; Rizzi, A.; Villetti, G. 1-Phenyl-2-monoalkyl carboxylic acid derivatives for the treatment of neurodegenerative diseases. WO2004/073705A1. 2004.
11. Raveglia, L.; Peretto, I.; Radaelli, S.; Imbimbo, B. P.; Rizzi, A.; Villetti, G. 1-Phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases. WO2004/07423241. 2004.
12. Peretto, I.; Radaelli, S.; Parini, C.; Zandi, M.; Raveglia, L. F.; Dondio, G.; Fontanella, L.; Misiano, P.; Bigogno, C.; Rizzi, A.; Riccardi, B.; Biscaioli, M.; Marchetti, S.; Puccini, P.; Catinella, S.; Rondelli, I.; Cenacchi, V.; Bolzoni, P. T.; Caruso, P.; Villetti, G.; Facchinetti, F.; Del, G. E.; Moretto, N.; Imbimbo, B. P. Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. J. Med. Chem. 2005, 48, 5705-5720.
13. 1-42 lowering agents. Pharmacol. Res. 2007, Jan.16, doi:10.1016/ j.phrs.2006.12.010.
14. Imbimbo, B. P.; Del Guidice, E.; Miccichè, F.; Colavito, D.; D'Arrigo, A.; Dalle Carbonate, M.; Villetti, G.; Facchinetti, F.; Volta, R.; Pietrini, V.; Leon, A. Long-term treatment with CHF5074, a novel flurbiprofen analogue, markedly reduces brain b-amyloid in Tg2576 transgenic mice. Neurodegenerative Dis. 2007, 4 (Suppl. 1), 274.
15. Ramsden, N.; Wilson, F.; Reid, A.; Reader, V.; Miller, W.; Harrison, R. J.; Sunose, M.; Hernandez-Perni, R.; Major, J.; Boussard, C.; Smelt, K.; Taylor, J.; Leformal, A.; Cansfield, A.; Burckhardt, S. (Biphenyl-3-yl)-carboxylic acids and derivatives thereof and their use in therapy. WO2005/110963A, 2005.
16. Wilson, F.; Reid, A.; Reader, V.; Harrison, R. J.; Sunose, M.; Hernandez-Perni, R.; Major, J.; Boussard, C.; Smelt, K.; Taylor, J.; Leformal, A.; Cansfield, A.; Burckhardt, S. (Biphenyl)carboxylic acids and derivatives thereof WO2006/045554A1, 2006.
17. Ramsden, N., Wilson, F.; Reid, A.; Reader, V.; Miller, W.; Harrison, R. J.; Sunose, M.; Hernandez-Perni, R.; Major, J.; Boussard, C.; Smelt, K.; Taylor, J.; Leformal, A.; Cansfield, A.; Burckhardt, S. Biphenyl-carboxylic acids and derivatives thereof and their use in therapy. WO2006/021441A1, 2006.
18. Blurton, P.; Burkamp, F.; Churcher, I.; Harrison, T.; Neduvelil, J. Arylacetic acid and related compounds for treatment of Alzheimer's disease. WO2006005558A1, 2006.
19. Hannam, J. C.; Kulagowski, J. J.; Madin, A.; Ridgill, M. P.; Seward, E. M. Piperidines and related compounds for treatment of Alzheimer's disease. WO2006/043064A1, 2006.
20. Narlawar, R.; Perez Revuelta, B. I.; Baumann, K.; Schubenel, R.; Haass, C.; Steiner, H.; Schmidt, B. N-Substituted carbazolyloxyacetic acids modulate Alzheimer associated gamma-secretase. Bioorg. Med. Chem. Lett. 2007, 17, 176-182.
21. Narlawar, R.; Perez Revuelta, B. I.; Haass, C.; Steiner, H.; Schmidt, B.; Baumann, K. Scaffold of the cycloaxygenase-2 (COX-2) inhibitor calprofen provides Alzheimer gamma-secretase modulators. J. Med. Chem. 2006, 49, 7588-7591.
22. Beher, D.; Bettati, M.; Checksfield, G. D.; Churcher, I.; Doughty, V. A.; Oakley, P. J. Quddus, A.; Teall, M. R.; Wrigley, J. D. Treatment of Alzheimer's disease and related conditions. WO2005/013985A1, 2005.
23. Beher, D.; Bettati, M.; Churcher, I.; Munzo, B.; Prasit, P.; Oakley, P. J.; Quddus, A.; Stock N. S.; Wrigley, J. D. 1-alkyl-3-thio-substituted indole-2-alkynoic acids useful for the treatment of Alzheimer's disease and related conditions. WO2005/054193A1, 2005.
24. Bettati, M.; Churcher, I.; Doughty, V. A.; Harrison, T.; Nizi, E.; Smith, A. Preparation of (4,5,6,7-tetrahydio-1H-indol-7-yl)acetic derivatives for treating or preventing diseases associated with deposition of b-amyloid peptide in the brain. WO2005/108362A1, 2005.
25. Kukar, T.; Murphy, M. P.; Eriksen, J. L,; Sagi, S. A.; Weggen, S.; Smith, T. E.; Ladd, T.; Khan, M. A.; Kache, R.; Beard, J.; Dodson, M.; Merit, S.; Ozols, V. V.; Anastasiadis, P. Z.; Das, P.; Fauq, A.; Koo, E. H.; Golde, T. E. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat. Med. 2005, 11, 545-550.
26. Czech, C.; Burns, M. P.; Vardanian, L.; Augustin, A.; Jacobsen, H.; Baumann, K.; Rebeck, G. W. Cholesterol independent effect of LXR agonist TO-901317 on gamma-secretase. J. Neurochem. 2007, Postprint, doi:10.1111/j.1471-4159.2007.04467.x.
27. Leipold, D. D.; Kantoci, D.; Murray, E. D., Jr.; Quiggle, D. D.; Wechter, W. J. Bioinversion of R-flurbiprofen to S-flurbiprofen at various dose levels in rat, mouse, and monkey. Chirality 2004, 16, 379-387.
28. Lanz, T. A.; Fici, G. J.; Merchant, K. M. Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J. Pharmacol. Exp. Ther. 2005, 312, 399-406.
29. Dvir, E.; Friedman, J. E.; Lee, J. Y.; Koh, J. Y.; Younis, F.; Raz, S.; Shapiro, I.; Hoffman, A.; Dahan, A.; Rosenberg, G.; Angel, I.; Kozak, A.; Duvdevani, R. A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoy1-2-[6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl]-sn-glycero-3-phosphatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. J. Pharmacol. Exp. Ther. 2006, 318, 1248-1256.
30. Cheng, S.; Comer, D. D.; Mao, L.; Balow, G. P.; Pleynet, D. Compounds and uses thereof in modulating Abets. WO2004/110350, 2004.
31. Wagner, S. L.; Kounnas, M. Z.; Tyree, C, M.; Cheng, S.; Danks, A. M.; Ackermann, E. J.; DiGreorgio, P. J.; Tanzi, R. E.; Standerman, K. A.; Velicelebi, G. Modulators of gamma-secretase activity that lower Abeta-42 levels without affecting Notch proteolytic processing. 7th International Conference AD/PD, Sorrento, Italy, 2005.
32. Watanabe, H.; Bernier, F.; Miyagawa, T. T. a. f. A. r. d. U. 2. 2. b. K. T.; Kawano, K.; Doi, E.; Kitazawa, N.; Shin, K.; Miyagawa, T.; Kaneko, T.; Ito, K.; Takaishi, M.; Sasaki, T.; Hagiwara, H. Cinnamide compound. US2006/004013A1, 2006.
33. Watanabe, H.; Bernier, F.; Miyagawa, T. Therapeutic agent for Abeta related disorders. US2006/241038A1, 2006.